Previous 10 | Next 10 |
Big Pharma has validated ROR1 therapies which are at the core of ONCT's oncology program. Despite initial enthusiasm for ONCT, the market no longer assigns any premium to its stock. Nonetheless, clinical results continue to be very positive, the company has engaged in additional p...
Today, we post our first research on a Busted IPO named Oncternal Therapeutics. The company is well funded at the moment and is focusing on advancing several candidates in its pipeline. A full investment analysis is presented in the paragraphs below. For further details see:...
Androgen Receptor (AR) inhibition is an important therapeutic approach for the treatment of Castration-Resistant Prostate Cancer (CRPC), but AR-escape mechanisms related to the expression of AR splice variants (AR-SV), such as AR-V7, represent a significant unmet need and are a key area...
SAN DIEGO and FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (“Oncternal”) (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, and Celularity Inc. (“Celularity”) (...
FLORHAM PARK, N.J. and SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”) (Nasdaq: CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternalȁ...
SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Aff...
Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Results Earnings Conference Call August 05, 2021, 5:00 pm ET Company Participants Richard Vincent - Chief Financial Officer James Breitmeyer - President, Chief Executive Officer Salim Yazji - Chief Medical Officer Conference Call Participants Hartaj...
Image source: The Motley Fool. Oncternal Therapeutics, Inc. (NASDAQ: ONCT) Q2 2021 Earnings Call Aug 05, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Oncternal Therapeutics, Inc. (ONCT) Q2 2021 Earnings Call Tran...
Oncternal Therapeutics (NASDAQ:ONCT): Q2 GAAP EPS of -$0.16. Revenue of $0.88M (+41.9% Y/Y) misses by $0.21M. Press Release For further details see: Oncternal Therapeutics misses on revenue
Presented encouraging interim clinical data for cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in a poster session at ASCO 2021 Expanded the ongoing Phase 1/2 study to evaluate cirmtuzumab plus ibrutin...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NASDAQ Market:
Oncternal Therapeutics Inc. Website:
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets c...
2024-07-26 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Pha...